European biotech chases record VC funding

NurPhoto/Getty Images

VC backing for European biotech startups is connected way for a grounds year, though the spread with the US remains stark.

According to PitchBook data, €800 cardinal (about $912 million) has been invested successful the abstraction this year, much than three-quarters of the full for 2025. At the existent pace, woody worth would surpass 2018's grounds of €1.2 billion.

The fig of VC rounds involving European biotech startups is expected to summation modestly from past year, dissimilar successful galore different sectors. However, the median woody size remains beneath 2024's precocious of €3.5 million.

Swiss radiopharmaceutical startup Nuclidium's 105 cardinal Swiss francs (about $130 million) Series B was the largest circular to adjacent this year. It is followed by a $115 cardinal Series A for London-based RQ Bio, which develops therapeutics to forestall influenza successful immunocompromised people.

Deal enactment has been supported by respective money closes this year. Paris-based Jeito Capital closed the largest VC fundraise this year, according to PitchBook's Q2 2026 European Venture Report, raising $1.2 cardinal for its 2nd vehicle. Fellow French capitalist Kurma Partners closed its 4th biotech money connected €215 million.

Europe accounts for a larger stock of planetary biotech funding, claiming 20.5% of the planetary total—the highest percent since 2018. But the spread betwixt the continent and much mature markets, specified arsenic the US, remains significant. US biotech startup fundraising is triple that of Europe this year, driven by a sharper absorption connected AI. The quality is exemplified by anti-aging startup NewLimit, which raised $435 cardinal past month.

Earlier this year, a radical of European VCs, including Denmark's Novo Holdings and France's Sofinnova Partners, launched The European Life Sciences Coalition successful concern with Invest Europe, calling for much capital, some nationalist and private, to beryllium injected into the region.

According to the ELSC, the manufacture supports 29 cardinal jobs, yet the continent struggles to clasp and standard startups. It pointed to fragmented superior markets, dilatory and uneven regulatory processes and a dwindling fig of specialized VC firms arsenic to wherefore homegrown startups are looking elsewhere.

The EU published a connection astatine the extremity of past twelvemonth to enactment the sector. The European Biotech Act is designed to trim the competitory spread with the US and China.

The enactment establishes a model for identifying strategical projects that would past payment from accelerated permitting and precedence entree to funding. Reducing time-to-market and harmonizing processes are cardinal focuses for the act, arsenic is mobilizing nationalist and backstage capital.

This nonfiction primitively appeared connected PitchBook News